Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $322.2 million.

  • Syndax Pharmaceuticals' Total Non-Current Liabilities rose 1610865000.0% to $322.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $322.2 million, marking a year-over-year increase of 1610865000.0%. This contributed to the annual value of $333.1 million for FY2024, which is 5655697.28% up from last year.
  • According to the latest figures from Q3 2025, Syndax Pharmaceuticals' Total Non-Current Liabilities is $322.2 million, which was up 1610865000.0% from $325.7 million recorded in Q2 2025.
  • In the past 5 years, Syndax Pharmaceuticals' Total Non-Current Liabilities ranged from a high of $333.1 million in Q4 2024 and a low of $2000.0 during Q3 2024
  • In the last 5 years, Syndax Pharmaceuticals' Total Non-Current Liabilities had a median value of $11.8 million in 2021 and averaged $75.3 million.
  • In the last 5 years, Syndax Pharmaceuticals' Total Non-Current Liabilities plummeted by 9976.85% in 2024 and then soared by 1610865000.0% in 2025.
  • Over the past 5 years, Syndax Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $20.6 million in 2021, then tumbled by 96.5% to $722000.0 in 2022, then fell by 18.56% to $588000.0 in 2023, then skyrocketed by 56556.97% to $333.1 million in 2024, then fell by 3.29% to $322.2 million in 2025.
  • Its Total Non-Current Liabilities was $322.2 million in Q3 2025, compared to $325.7 million in Q2 2025 and $331.1 million in Q1 2025.